Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

Cited In for PubMed (Select 18565863)

1.

Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy.

Butts CA.

Transl Lung Cancer Res. 2013 Oct;2(5):415-22. doi: 10.3978/j.issn.2218-6751.2013.10.09. Review.

2.

Immune approaches to the treatment of breast cancer, around the corner?

Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G.

Breast Cancer Res. 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620.

3.

Hierarchy in gene expression is predictive of risk, progression, and outcome in adult acute myeloid leukemia.

Tripathi S, Deem MW.

Phys Biol. 2015 Feb 16;12(1):016016. doi: 10.1088/1478-3975/12/1/016016.

PMID:
25685944
4.

InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity.

Zhou F, Li X, Naylor MF, Hode T, Nordquist RE, Alleruzzo L, Raker J, Lam SS, Du N, Shi L, Wang X, Chen WR.

Cancer Lett. 2015 Apr 10;359(2):169-77. doi: 10.1016/j.canlet.2015.01.029. Epub 2015 Jan 26. Review.

PMID:
25633839
5.

Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.

Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F, Jiang J, Wu C, Zhang X, Chen X, Turnquist H, Zhu Y, Lu B.

J Immunol. 2015 Jan 1;194(1):438-45. doi: 10.4049/jimmunol.1401344. Epub 2014 Nov 26.

PMID:
25429071
6.

Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation.

Hefetz-Sela S, Stein I, Klieger Y, Porat R, Sade-Feldman M, Zreik F, Nagler A, Pappo O, Quagliata L, Dazert E, Eferl R, Terracciano L, Wagner EF, Ben-Neriah Y, Baniyash M, Pikarsky E.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17582-7. doi: 10.1073/pnas.1409700111. Epub 2014 Nov 24.

PMID:
25422452
7.

Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.

Humar M, Azemar M, Maurer M, Groner B.

Front Oncol. 2014 Oct 6;4:270. doi: 10.3389/fonc.2014.00270. eCollection 2014.

8.

Cancer immunotherapy in clinical practice -- the past, present, and future.

Goel G, Sun W.

Chin J Cancer. 2014 Sep;33(9):445-57. doi: 10.5732/cjc.014.10123.

9.

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone.

Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HM.

BMC Palliat Care. 2014 Aug 20;13:42. doi: 10.1186/1472-684X-13-42. eCollection 2014.

10.

NKT Cell Responses to B Cell Lymphoma.

Li J, Sun W, Subrahmanyam PB, Page C, Younger KM, Tiper IV, Frieman M, Kimball AS, Webb TJ.

Med Sci (Basel). 2014 Jun 1;2(2):82-97.

11.

Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.

Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, Suehiro Y, Yamasaki T, Hinoda Y, Oka M.

J Transl Med. 2014 Jun 19;12:175. doi: 10.1186/1479-5876-12-175.

12.

A role for T-lymphocytes in human breast cancer and in canine mammary tumors.

Carvalho MI, Pires I, Prada J, Queiroga FL.

Biomed Res Int. 2014;2014:130894. doi: 10.1155/2014/130894. Epub 2014 Feb 2.

13.

Autoimmunity as a double agent in tumor killing and cancer promotion.

Toomer KH, Chen Z.

Front Immunol. 2014 Mar 18;5:116. doi: 10.3389/fimmu.2014.00116. eCollection 2014. Review.

14.

Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.

Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, Wu X, Cheng X, Xing X, Du H, Wang X, Hu Y, Ji J.

Chin J Cancer Res. 2014 Feb;26(1):104-11. doi: 10.3978/j.issn.1000-9604.2014.02.08.

15.

The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma.

Kimball AS, Webb TJ.

Mol Cell Pharmacol. 2013 Jan 1;5(1):27-38.

16.

Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.

Bauzon M, Hermiston T.

Front Immunol. 2014 Feb 24;5:74. doi: 10.3389/fimmu.2014.00074. eCollection 2014. Review.

17.

Involvement of a non-human sialic Acid in human cancer.

Samraj AN, Läubli H, Varki N, Varki A.

Front Oncol. 2014 Feb 19;4:33. doi: 10.3389/fonc.2014.00033. eCollection 2014. Review.

18.

Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma.

Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S.

PLoS One. 2014 Feb 10;9(2):e88133. doi: 10.1371/journal.pone.0088133. eCollection 2014.

19.

Modifying tumor-associated macrophages: An important adjunct to immunotherapy.

Fridlender ZG, Albelda SM.

Oncoimmunology. 2013 Dec 1;2(12):e26620. Epub 2013 Oct 21.

20.

Immunotherapy for solid tumors--a review for surgeons.

Saied A, Pillarisetty VG, Katz SC.

J Surg Res. 2014 Apr;187(2):525-35. doi: 10.1016/j.jss.2013.12.018. Epub 2013 Dec 25. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk